Covaxin crosses half-way mark in phase 3 clinical trials

Hyderabad based pharma giant Bharat Biotech has announced successful recruitment of 13,000 volunteers for the Phase-3 clinical trial of anti-COVID-19 vaccine COVAXIN across multiple sites in

The Phase III human clinical trials of COVAXIN which began mid-November targeted to be done in 26,000 volunteers across India.

This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.



Leave a Reply

Your email address will not be published. Required fields are marked *

Our YouTube ChannelOur Facebook PageOur Twitter PageOur LinkedIn PageOur Instagram PageOur Whatsapp NumberYour Idea